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   AT-2266 is a new antibiotic of the pyridone carboxylic acid class which possesses a broad, low-
MIC antibacterial spectrum. Therapeutic studies were carried out on the use of this drug in the 
treatment of chronic prostatitis, and at the same time a pathological analysis was performed on chron-
ic prostatitis. 
   The subjects were 97 chronic prostatitis patients for whom the prostate fluid had been confirmed 
to contain at least 30 leukocytes per 400-power magnification field. An analysis of the background 
factors revealed that 71% of these patients had a past history of gonorrheal or non-gonorrheal ure-
thritis. Culture of the prostate fluid yielded gram-positive cocci (S. epidermidis in most cases) in 44.1 
% of the patients. E. coli was detected in 3.2% of the patients, while the remaining cases gave 
negative cultures. In 53.9% of the patients who had not been receiving therapy prior to inclusion 
in this study, the subjective symptoms consisted of urethral irritation or irritation upon urination. 
In the other patients, the relationship of the complaints to the disease could not be clearly estab-
lished. In the patients who had been receiving therapy, the majority did not complain of subjec-
tive symptoms. 
   AT-2266 was administered in a daily dosage of 600 mg (in 3 divided doses) for 14 days. The 
therapeutic efficacy was evaluated. At the end of 7 days of AT-2266 therapy, 15.5% of the previ-
ously-untreated group and 8% of the previously-treated group were "excellent" cases, and the effi-
cacy rate was 32.8% and 36%, respectively, when the "good" cases were also included. At the end 
of the full 14 days of therapy, the corresponding efficacy rates were 21.7% and 17.4%, and 54.3% 
and 56.5%. 
   Considerable improvement was achieved in the subjective symptoms of urethral irritation and 
irritation upon urination at the end of 7 days of therapy, and the improvement was even greater 
following the next 7 days of treatment. With regard to the complaints for which the relationship 
to the disease could not be clearly established, however, the improvement was not very good: there 
was not much difference between the results on the 7th and 14th days, and the elimination rate 
even after 14 days was slightly below 30%. In the previously-untreated patients, improvement in
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leukocyte  count in the prostate fluid to 10 or fewer cells per microscopic field was achieved in 
15.6% at 7 days and 21.7% at 14 days. 
   As side effects of AT-2266, mild symptoms were observed to occur in only 1.8% of the patients.
Key words: Chronic prostatitis, Therapeutic result, Enoxacin
は じ め に




























が残った ものもあ る.そ のため対象症例の31例(32














































































































Table4.投与 前 前 立 腺 液 中 の
Clumpsの程 度



















る.尿道炎既往が71%とい う所 見は注 目される.それ
ら治療症例の前立腺分泌液中の白血球(す べて400倍
視野30個以上)を検索する時clumpingが認められ


















Table5.投与 前 菌 の 分 布




























小 計 93(100。0) 28 65
未 検 査 4 3 1










































































































s・θ曜8辮 雌5に 対 す るMIcの 分布(106CFu/ml)
Table6.総合臨床効果判定基準
著 効 自覚症状 があるもの は、それが消失 し、かつ投与後の















Table7.総合 臨 床 効 果
判定 著 効 有 効


















判定 著 効 有 効療




























































































































果を検討した.そ れを直前他治療を受けて いた もの
と,未 治療iとに分けて分析してみたのがTablc9で
ある.A症 状を持つA群 及びA+B群 では,7日 でも
一応効果は出るが,14日になるとより治療効果が著し





















既 治 療 群
嚢 治療期聞判定 著 効 有
未 治 療 群






































































































































































Table11.治療 に よ るclumps所見 の推 移
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